FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.
What happened
FDA inspected Penn Herb's Philadelphia facility from May 12 through June 8, 2026, and reviewed product labels collected during the inspection. FDA found CGMP violations for dietary supplements, including missing specifications and unsanitary conditions, and said the company had not responded to the Form FDA 483 (inspection observations). FDA also noted that the Black Walnut Hulls label did not declare tree nuts (walnut) as a major food allergen.
What FDA found
Penn Herb did not establish identity specifications for Mexican Sarsaparilla Root and Black Walnut Hulls; its checks used only appearance, color, taste and aroma, which FDA said cannot confirm species identity.
21 CFR 111.70(b)(1)Penn Herb did not set limits for microbes and heavy metals that may contaminate Ashwagandha Root, Mexican Sarsaparilla Root and Black Walnut Hulls.
21 CFR 111.70(b)(3)Penn Herb did not set finished-product specifications for identity, purity, strength, composition and contamination; the only listed specification was capsule weight in milligrams.
21 CFR 111.70(e)FDA saw debris from prior runs on food-contact surfaces of the encapsulator and powder on floors, walls and ceilings, including residue after cleaning before a production run.
21 CFR 111.360Penn Herb collected residual powder with worn tools and reused it in later production, and it could not show its sanitizer was safe for food-contact surfaces; a hand sink was out of order and opened bulk ingredient bags were taped shut with dust on exteriors.
21 CFR 111.360The Black Walnut Hulls label declared black walnut hulls but did not declare tree nuts (walnut) as a major food allergen.
section 403(w)(1) of the Act
What FDA wants
FDA asks Penn Herb to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with supporting documents. If corrective actions cannot be completed in that time, the company must state why and give the expected completion time.
Who should pay attention
- dietary supplement brands that buy botanicals from this manufacturer
- contract manufacturers and repackagers of powdered botanicals
- quality teams handling allergen labeling and CGMP sanitation
This is a summary. Read the original letter on fda.gov.